Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sweden-based biopharmaceutical company Diamyd Medical has acquired an exclusive license for Endomorphin technology that may be used for the treatment of pain, including neuropathic pain that occurs in diabetes.
Subscribe to our email newsletter
According to Diamyd Medical, the Endomorphin technology embodies a direct production and release of endomorfin peptides with morphine-like activity directly into the spinal cord blocking further pain signal generation.
Elisabeth Lindner, president and CEO of Diamyd Medical, said: “In addition to this newly acquired Endomorphin technology, and our exclusive licenses for generalized anxiety disorder (GAD), we also have an ongoing clinical development program with enkephalin.
“With enkephalin, GAD and Endomorphin, we have completed our pain portfolio now having products targeting all three major pain receptors. This gives us a strong position in the development of products for multiple pain types, including neuropathic pain that alone has a market potential estimated to more than $3.5 billion.”